ORTHO SALESBRIEF

Issue 1 · Nov 17, 2026

U.S. knees drag Smith+Nephew to a lower 2026 outlook

ISSUE 1 · NOV 17, 2026
U.S. knees drag Smith+Nephew to a lower 2026 outlook
ORTHO SALES BRIEF

Smith+Nephew's U.S. knee sales fall 7.3%, Zimmer Biomet's knees slip while hips grow, and CMS sets 2027 ASC rates.

The Big Picture: Third quarter results put U.S. knees at the center of the week. Smith+Nephew's U.S. knee sales fell 7.3% and it cut its 2026 outlook. Zimmer Biomet's knees slipped 3.1% while hips, sports and extremities grew. CMS set 2027 outpatient and ASC rates.

The Big Story: U.S. knees drag Smith+Nephew to a lower 2026 outlook

Smith+Nephew reported third quarter revenue of $1,551 million on Nov 4, up 3.4%. Orthopaedics returned to growth at $590 million, up 2.3%, but the U.S. joint business did not. U.S. knee implant revenue fell 7.3% and U.S. hip implants fell 1.0%.

The company now expects underlying revenue growth of about 3% for 2026, down from about 4%, and trading profit growth of about 4%, down from about 8%. It said the slower U.S. orthopaedics growth will continue through the fourth quarter.

Smith+Nephew also confirmed that its talks with Johnson & Johnson about a combination involving orthopaedics have ended. It will keep exploring the full range of options for that business. On the product side, its cementless LANDMARK knee received 510(k) clearance, and the first U.S. cases are done.

Who it affects: Hip and knee reps at every major maker, plus the agencies and distributors that carry Smith+Nephew recon.

Why it matters: Two of the big recon makers say U.S. knees are soft going into year end contracting. Expect sharper price talks on knees, and expect competitors to call on Smith+Nephew knee accounts while its orthopaedics future is unsettled.

Sources: Smith+Nephew Q3 trading update (SEC), Becker's Spine Review

New here? Get this in your inbox.

A free five minute brief every Tuesday morning, written for the people who sell into this industry.

Get it free every Tuesday

CMS sets 2027 hospital outpatient and ASC rates

CMS issued its final 2027 outpatient and ASC payment rule on Nov 4, with a 2.3% update for both hospital outpatient departments and ASCs. It removes 637 more services from the inpatient only list in year two of a three year phase out.

The families CMS listed for removal this year are not musculoskeletal. The big orthopedic shift came in the 2026 rule, which took 285 musculoskeletal procedures off the inpatient only list.

Why it matters: A 2.3% raise does little for ASC margins on implant heavy cases, so ASC buyers will keep pushing on implant price when 2027 contracts come up.

Sources: CMS fact sheet, AAHKS summary

Earnings Watch

  • Zimmer Biomet (Nov 4): Sales of $2.063 billion, up 3.1% (3.7% in constant currency). Knees fell 3.1% to $767.5 million. Hips rose 6.0% to $536.5 million, and sports, extremities and trauma rose 6.8%. Zimmer raised its organic growth outlook to 3.0% to 3.5%, from 2.25% to 3.25%.
  • Globus Medical (Nov 5): Sales of $763.7 million, down 0.7%. U.S. spine grew 2% and enabling technologies 24%, but Nevro product sales fell to $73.7 million from $99.3 million. Globus cut its 2026 revenue forecast to $3.09 billion, from $3.18 billion to $3.22 billion.
  • Enovis (Nov 5): Sales of $559 million, up 2% reported and 5% organic. Reconstructive grew 6%, with U.S. recon up 4.9%. Enovis raised its adjusted EPS outlook to $3.58 to $3.79.

Hips, sports and extremities are growing; knees are the soft spot.

Sources: Zimmer Biomet release (SEC), Globus Medical release (SEC), Enovis release (SEC)

Regulation Watch

restor3d recalls a reverse shoulder liner. FDA posted a Class 2 recall on Nov 3 for 40mm polymer liners used with sizes 1 and 2 of the Veritas Reverse Total Shoulder. The pairing can overload the liner, which may lack retention strength and lead to dislocation. 240 units are affected. FDA recall Z-0348-2027

THE NUMBER
7.3%

How far Smith+Nephew's U.S. knee implant revenue fell in the third quarter. Source

Talk Track

Three questions to ask your surgeons and hospital buyers this week:

  1. Are your knee cases holding into December, or are patients pushing surgery into next year?
  2. What has your Smith+Nephew rep told you about where its orthopaedics business is headed?
  3. With a 2.3% ASC update for 2027, what are you asking implant vendors for in next year's contract?

Know the case calendar before the year end price talk.

Jobs

  • Our picks this week. We could confirm only four new roles, so all of them are here.
  • Regional Manager, Sports, Arthrex (Houston; Texas and Oklahoma territory). Leads an independent sales agency. Targeted cash pay of $200,000 to $250,000. Posted Nov 16. Apply
  • Regional Manager, Sports Medicine, Arthrex (Orlando; Florida territory). Targeted cash pay of $200,000 to $250,000. Posted Nov 16. Apply
  • Sales Representative, Joint Replacement, Stryker (Denver). Field role selling hips and knees and supporting cases in the OR. Commission based. Posted Nov 10. Apply
  • Joint Replacement Sales Associate, Stryker (Albuquerque). An entry role covering cases with mentoring from the reps. $60,100 to $76,800 listed. Posted Nov 5. Apply

What We're Watching

  • DePuy Synthes: On Oct 13, J&J said it is on track to separate the business by mid-2027 and is leaning toward a spin. MassDevice

We're looking for industry advisors and contributors

We want reps, agency owners, sales managers and hospital value analysis people who can tell us what they see in the OR and at the contract table. Send a tip, give an issue a quick read before it goes out, or write a short piece now and then.

You get credit by name in the brief. That is the whole offer.

Raise your hand here, with a line about your role.

Forward this to someone on your team who'd use it.

The Editorial Team

Reading this on the web?

A free five minute brief every Tuesday morning, written for the people who sell into this industry.

Get it free every Tuesday

Ortho Sales Brief is an independent publication by its editorial team. Nothing here is investment advice.